fingolimod (Gilenya, FTY720)

From Aaushi
Jump to navigation Jump to search

Indications

Contraindications

Pregnancy category: C (contraindicated during pregnancy)[7]

Dosage

Monitor

Adverse effects

Mechanism of action

More general terms

References

  1. Kappos L et al A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis NEJM www.nejm.org January 20, 2010 http://content.nejm.org/cgi/content/full/NEJMoa0909494
  2. Cohen JA et al Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis NEJM www.nejm.org January 20, 2010 http://content.nejm.org/cgi/content/full/NEJMoa0907839
  3. FDA MedWatch, May 14, 2012 Gilenya (fingolimod): Drug Safety Communication - Safety Review of a Reported Death After the First Dose http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm284355.htm
  4. FDAA MedWatch Gilenya (fingolimod) - Drug Safety Communication: Investigating Rare Brain Infection http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm366751.htm
  5. 5.0 5.1 GILENYA (fingolimod) capsules HIGHLIGHTS OF PRESCRIBING INFORMATION http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf
  6. FDA Safety Alert. August 4, 2015 Gilenya (fingolimod): Drug Safety Communication - FDA Warns About Cases of Rare Brain Infection. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm457183.htm
  7. 7.0 7.1 7.2 7.3 Medical Knowledge Self Assessment Program (MKSAP) 17, 18. American College of Physicians, Philadelphia 2015, 2018
  8. 8.0 8.1 FDA News Release. May 11, 2018 FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients. First drug approved to treat MS in ages 10 and older. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm607501.htm
  9. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012 Feb 28;78(9):672-80. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22371414
  10. 10.0 10.1 FDA Safety Alert. Nov 20, 2018 Gilenya (fingolimod): Drug Safety Communication - Severe Worsening of Multiple Sclerosis After Stopping the Medicine. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm626264.htm